Treatment with trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER-2) to target the HER-2 pathway, significantly improves outcomes for women with HER-2-positive breast cancer [1-3]. This evidence concerns the gene ERBB2 and breast cancer.